Quantcast

Latest Organofluorides Stories

2014-07-31 12:28:49

Delivering novel fluorination tools for drug and material development SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Catylix, Inc.

2014-07-30 08:33:01

Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.

2014-07-30 08:32:55

- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y., July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and

2014-07-28 04:21:34

HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data

2014-07-27 23:01:51

The Firm is currently representing clients in Risperdal lawsuits that similarly allege the atypical antipsychotic medication caused gynecomastia, a condition categorized by male breast development.

2014-07-23 23:16:39

The Firm is representing numerous clients in Risperdal lawsuits who allegedly developed gynecomastia, or male breast growth, due to their use of the atypical antipsychotic medication.

2014-07-22 08:32:36

Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO, July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.

2014-07-17 16:26:09

NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company.

2014-07-16 23:03:02

North America is a dominant market for PVDF owing to significant demand from the U.S.


Word of the Day
swell-mobsman
  • A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
Use of the word 'swell-mobsman' dates at least to the early 1800s.